Approval and launch of a short-acting insulglargine biologic for Type 1 diabetes on October 23, 2026, expand BIONPHARMA’s insulin portfolio with a differentiated formulation poised to capture share in the value-based marketplace. This regulatory milestone strengthens the company’s revenue visibility and underpins its strategy to drive growth through the widespread adoption of competitive biosimilars in the insuliglargine segment.